S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

Dr Usmani discusses the FDA approval of cilta-cel for relapsed/refractory multiple myeloma patients who have had at least 1 prior line of therapy. Topics include comparing CAR-T cell therapy benefits to standard care regimens, impacts on earlier treatment settings, patient accessibility, a comparative study of cilta-cel vs. standard care regimens, FDA advisory committee meeting insights, safety, and the role of cilta-cel in multiple myeloma treatment.